MedTrace Logo

Cat-PAD Follow on Study

NCT01272323 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 170

Last updated 2011-05-20

No results posted yet for this study

Summary

Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis and/or asthma.

The purpose of this optional observational follow-on study is to further evaluate rhinoconjunctivitis symptoms on exposure to cat dander in the EEC among subjects who completed all dosing visits in study CP005 approximately one year after the start of treatment.

Conditions

  • Cat Allergy
  • Rhinoconjunctivitis

Interventions

BIOLOGICAL

Placebo

No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.

BIOLOGICAL

Cat-PAD Dose 1

No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.

BIOLOGICAL

Cat-PAD Dose 2

No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.

Sponsors & Collaborators

  • Cetero Research, San Antonio

    collaborator NETWORK

  • Adiga Life Sciences, Inc.

    collaborator INDUSTRY

  • Circassia Limited

    lead INDUSTRY

Principal Investigators

  • Peter Couroux, MD · Cetero Research, San Antonio

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2011-04-30
Completion
2011-04-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01272323 on ClinicalTrials.gov